Zhen Huang
A5103833265- Antiplatelet Therapy and Cardiovascular Diseases
- Acute Myocardial Infarction Research
- Tryptophan and brain disorders
- Atrial Fibrillation Management and Outcomes
- Cardiac Imaging and Diagnostics
- Stress Responses and Cortisol
- Venous Thromboembolism Diagnosis and Management
- Peripheral Artery Disease Management
- Coronary Interventions and Diagnostics
- Neuroscience and Neuropharmacology Research
- Cardiovascular Function and Risk Factors
- Neurological Disease Mechanisms and Treatments
- Blood Pressure and Hypertension Studies
- Traditional Chinese Medicine Analysis
- Pharmacological Effects of Natural Compounds
- Neuroinflammation and Neurodegeneration Mechanisms
- Piperaceae Chemical and Biological Studies
- Heart Failure Treatment and Management
- Systemic Lupus Erythematosus Research
- Nerve injury and regeneration
- Opioid Use Disorder Treatment
- Substance Abuse Treatment and Outcomes
- Cerebrovascular and Carotid Artery Diseases
- Cardiac Health and Mental Health
- Influenza Virus Research Studies
Zhejiang Chinese Medical University
2012-2025
Clinical Research Institute
2016-2025
Duke University
2010-2025
Renmin University of China
2024
Shanghai Children's Medical Center
2024
Shanghai Jiao Tong University
2024
Guangxi Medical University
2024
Association Clinique et Thérapeutique Infantile du Val de Marne
2023-2024
Zhejiang University
2024
Huazhong University of Science and Technology
2016-2024
Vorapaxar is a new oral protease-activated-receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation.In this multinational, double-blind, randomized trial, we compared vorapaxar with placebo in 12,944 patients who had acute coronary syndromes without ST-segment elevation. The primary end point was composite of death from cardiovascular causes, myocardial infarction, stroke, recurrent ischemia rehospitalization, or urgent revascularization.Follow-up the trial terminated...
<h3>Context</h3>No randomized trials have examined treatments for prescription opioid dependence, despite its increasing prevalence.<h3>Objective</h3>To evaluate the efficacy of brief and extended buprenorphine hydrochloride–naloxone hydrochloride treatment, with different counseling intensities, patients dependent on opioids.<h3>Design</h3>Multisite, clinical trial using a 2-phase adaptive treatment research design. Brief (phase 1) included 2-week buprenorphine-naloxone stabilization,...
Clinical trials that have assessed the effect of revascularization in patients with stable coronary disease routinely excluded those advanced chronic kidney disease.
The ISCHEMIA trial (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches) postulated that patients with stable coronary artery disease (CAD) moderate or severe ischemia would benefit from revascularization. We investigated the relationship between severity CAD outcomes, overall by management strategy. In total, 5179 were randomized to an initial invasive conservative Blinded, core laboratory-interpreted computed tomographic angiography was used assess...
The ISCHEMIA trial (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches) compared an initial invasive versus conservative management strategy for patients with chronic coronary disease moderate or severe ischemia, no major difference in most outcomes during a median 3.2 years. Extended follow-up mortality is ongoing.
Background: Acute limb ischemia (ALI) is an important clinical event and emerging cardiovascular trial outcome. Risk factors for outcomes after ALI have not been fully evaluated. Methods: EUCLID (Examining Use of Ticagrelor in Peripheral Artery Disease) randomized patients with peripheral artery disease to ticagrelor versus clopidogrel. Enrollment criteria included ankle-brachial index ≤0.80 or previous lower extremity revascularization. Patients were grouped according the primary outcome,...
Abstract Objectives : Our objective was to analyze the impact of arterial access site, sheath size, timing removal, and use site closure devices on high‐risk patients with acute coronary syndromes (ACS). Background In SYNERGY trial, 9,978 ACS were randomly assigned receive enoxaparin or unfractionated heparin. Methods This analysis includes 9,404 for whom information obtained first PCI procedure diagnostic catheterization. Comparisons baseline, angiographic, procedural characteristics...
The Bleeding Academic Research Consortium (BARC) scale has been proposed to standardize bleeding endpoint definitions and reporting in cardiovascular trials. Validation large cohorts of patients is needed. This study sought investigate the relationship between BARC-classified mortality compared its prognostic value against 2 validated scales: TIMI (Thrombolysis In Myocardial Infarction) GUSTO (Global Use Strategies Open Occluded Arteries). We analyzed 12,944 with acute coronary syndromes...
Neuronal damage is related to the onset and treatment of depressive disorders. Antidepressant-like effects have been elicited by paeoniflorin on animal models. The aim this study demonstrate whether neuroprotective effect rats suffered from chronic unpredictable mild stress (CUMS) was regulated ERK-CREB signaling pathway. Results showed that not only ameliorated depressive-like behavior with low locomotor activity prolonged immobility duration in our forced swimming test but also reduced...
In 2013, the Trial to Assess Chelation Therapy (TACT) reported that edetate disodium (EDTA)-based chelation significantly reduced cardiovascular disease (CVD) events by 18% in 1708 patients with a prior myocardial infarction (MI).
The elderly constitute an increasing proportion of acute myocardial infarction patients and have disproportionately high mortality morbidity. Those with heart failure or impaired left ventricular function after complication rates. Little is known about outcomes contemporary therapies in these patients.The Valsartan Acute Myocardial Infarction Trial (VALIANT) randomized 14,703 and/or ejection fraction <40% to receive captopril, valsartan, both. Mortality a composite end point, including...
Abstract The present study investigated the antidepressant effect of ethanol extract Paeonia lactiflora (EPL) in mice using forced swim test, tail suspension open‐field test and reserpine test. Our results showed that intragastric administration EPL at doses 250 500 mg/kg for seven days significantly reduced duration immobility both dose was as effective positive control (chlorimipramine, 20 mg/kg) these tests. However, treatments did not affect number crossing rearing Treating with...